{"nctId":"NCT01100307","briefTitle":"A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema","startDateStruct":{"date":"2010-05"},"conditions":["Macular Edema","Diabetic Mellitus","Retinal Disease"],"count":243,"armGroups":[{"label":"pegaptanib sodium","type":"EXPERIMENTAL","interventionNames":["Drug: pegaptanib sodium"]},{"label":"sham injection","type":"SHAM_COMPARATOR","interventionNames":["Other: sham injection"]}],"interventions":[{"name":"pegaptanib sodium","otherNames":[]},{"name":"sham injection","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type I, or Type II diabetic subjects\n* Subjects must have macular edema that involves the center field of the macula 3. Foveal thickness of at least 250 μm 4. Best corrected distance visual acuity in the study eye must be a letter score between 68 and 35 inclusive\n\nExclusion Criteria:\n\n* Eyes with prior panretinal photocoagulation (PRP) less than 4 months prior to baseline eyes in which PRP is needed now or is likely to be needed within the next 9 months\n* HbA1C level \\>12% or recent signs of uncontrolled diabetes\n* Atrophy/scarring/fibrosis involving the center of the macula, including evidence of laser treated atrophy","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Experience a ≥10 Letter Improvement of Visual Acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline at Week 24: Double Masked Phase","description":"Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Acuity (VA): Double Masked Phase","description":"Changes in VA were monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey ETDRS charts","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"5.39"},{"groupId":"OG001","value":"0.2","spread":"5.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"6.19"},{"groupId":"OG001","value":"-0.6","spread":"8.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"7.84"},{"groupId":"OG001","value":"0.1","spread":"8.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"7.50"},{"groupId":"OG001","value":"-1.2","spread":"8.80"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Underwent Focal/Grid Laser, or Vitrectomy: Double Masked Phase","description":"Included focal laser photocoagulation, grid laser photocoagulation, and vitrectomy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experience a ≥10 Letter Improvement of Visual Acuity in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline at Week 54: Open Phase","description":"Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Acuity (VA): Open Phase","description":"Changes in VA were monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"8.62"},{"groupId":"OG001","value":"-0.1","spread":"7.78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"8.43"},{"groupId":"OG001","value":"0.6","spread":"7.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"8.27"},{"groupId":"OG001","value":"0.3","spread":"8.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"8.52"},{"groupId":"OG001","value":"-0.8","spread":"10.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"8.93"},{"groupId":"OG001","value":"-0.5","spread":"10.48"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Underwent Focal/Grid Laser, or Vitrectomy: Open Phase","description":"Included focal laser photocoagulation, grid laser photocoagulation, and vitrectomy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Visual Acuity Over Time at Each Time Point: Double Masked Phase","description":"Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":"8.39"},{"groupId":"OG001","value":"56.9","spread":"8.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":"8.24"},{"groupId":"OG001","value":"57.1","spread":"10.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":"9.32"},{"groupId":"OG001","value":"56.4","spread":"11.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.7","spread":"9.66"},{"groupId":"OG001","value":"57.1","spread":"11.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.9","spread":"9.89"},{"groupId":"OG001","value":"55.7","spread":"12.18"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Distribution of Change From Baseline of Visual Acuity (VA) at Each Time Point: Double Masked Phase","description":"Best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts.\n\nChange from baseline in VA was categorized as follows: Lost 15 letters or more; Lost 10 - 14 letters; Lost 1 - 9 Letters; No change or gained 1 - 9 letters; Gained 10 - 14 letters; Gained 15 letters or more.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Experience a ≥10 Letter Improvement of Visual Acuity in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline: Double Masked Phase","description":"Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Experience a ≥15, ≥5, or ≥0 Letter Improvement of Visual Acuity in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline at Week 24: Double Masked Phase","description":"Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Exhibiting a Decrease From Baseline in Retinal Thickness at the Center Point by ≥25 Percent and ≥50 Percent Using Optical Coherence Tomography (OCT) at Week 24: Double Masked Phase","description":"OCT, a noninvasive, noncontact, transpupillary imaging technology, was utilized to image retinal structures in vivo. The anatomic layers within the retina, retinal thickness could be measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Composite Score/Sub-scale Score at Week 24: Double Masked Phase","description":"NEI-VFQ 25, Japanese version v.1.4 for self-administering questionnaires consisted of the base set of 25 questions and 12 subscale scores.\n\nResponse categories to each question were converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. A higher score represented better functioning. Questions within each sub-scale were averaged together to create the 12 sub-scale scores. The overall composite score was calculated by averaging the vision-targeted subscale scores excluding the general health-rating question.\n\nPositive change indicated improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"18.80"},{"groupId":"OG001","value":"-2.1","spread":"20.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"17.80"},{"groupId":"OG001","value":"0.7","spread":"19.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"18.35"},{"groupId":"OG001","value":"0.6","spread":"18.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"19.01"},{"groupId":"OG001","value":"0.6","spread":"18.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"15.92"},{"groupId":"OG001","value":"-1.3","spread":"15.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"17.77"},{"groupId":"OG001","value":"-1.7","spread":"17.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"19.05"},{"groupId":"OG001","value":"-0.5","spread":"17.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"23.36"},{"groupId":"OG001","value":"-1.1","spread":"21.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"18.11"},{"groupId":"OG001","value":"-1.1","spread":"18.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"14.34"},{"groupId":"OG001","value":"-5.7","spread":"20.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"15.67"},{"groupId":"OG001","value":"-0.9","spread":"19.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"23.15"},{"groupId":"OG001","value":"-4.1","spread":"21.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"10.37"},{"groupId":"OG001","value":"-1.1","spread":"10.85"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Visual Acuity Over Time at Each Time Point: Open Phase","description":"Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.2","spread":"8.07"},{"groupId":"OG001","value":"56.7","spread":"8.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":"10.52"},{"groupId":"OG001","value":"56.6","spread":"11.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.6","spread":"10.47"},{"groupId":"OG001","value":"57.3","spread":"11.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.5","spread":"10.01"},{"groupId":"OG001","value":"57.0","spread":"12.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":"10.11"},{"groupId":"OG001","value":"55.9","spread":"13.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.8","spread":"10.63"},{"groupId":"OG001","value":"56.2","spread":"13.71"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Distribution of Change From Baseline of Visual Acuity (VA) at Each Time Point: Open Phase","description":"Best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts.\n\nChange from baseline in VA was categorized as follows: Lost 15 letters or more; Lost 10 - 14 letters; Lost 1 - 9 Letters; No change or gained 1 - 9 letters; Gained 10 - 14 letters; Gained 15 letters or more.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Experience a ≥10 Letter Improvement of Visual Acuity in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline: Open Phase","description":"Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Who Experience a ≥15, ≥5, or ≥0 Letter Improvement of Visual Acuity in Early Treatment Diabetic Retinopathy Study (ETDRS) Chart From Baseline at Week 54: Open Phase","description":"Best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Exhibiting a Decrease From Baseline in Retinal Thickness at the Center Point by ≥25 Percent and ≥50 Percent Using Optical Coherence Tomography (OCT) at Week 54: Open Phase","description":"Retinal thickness was assessed by spectral-domain optical coherence tomography or OCT3000, a non-invasive imaging technique that uses long-wavelength light to capture micrometer-resolution cross-sectional images from biological tissue.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in The 25-Item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) Composite Score/Sub-scale Score at Week 54: Open Phase","description":"NEI-VFQ 25, Japanese version v.1.4 for self-administering questionnaires consisted of the base set of 25 questions and 12 subscale scores.\n\nResponse categories to each question were converted to a 0 to 100 scale so that the lowest and highest possible scores were set at 0 and 100 points, respectively. A higher score represented better functioning. Questions within each sub-scale were averaged together to create the 12 sub-scale scores. The overall composite score was calculated by averaging the vision-targeted subscale scores excluding the general health-rating question.\n\nPositive change indicated improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"20.13"},{"groupId":"OG001","value":"-1.8","spread":"20.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"15.68"},{"groupId":"OG001","value":"0.7","spread":"17.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"17.15"},{"groupId":"OG001","value":"0.0","spread":"17.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"17.28"},{"groupId":"OG001","value":"-0.6","spread":"19.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"15.97"},{"groupId":"OG001","value":"-0.5","spread":"15.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"17.92"},{"groupId":"OG001","value":"-2.5","spread":"17.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"19.85"},{"groupId":"OG001","value":"-2.7","spread":"20.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"23.34"},{"groupId":"OG001","value":"-0.6","spread":"20.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"19.30"},{"groupId":"OG001","value":"-3.3","spread":"18.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":"18.28"},{"groupId":"OG001","value":"-7.2","spread":"26.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"15.00"},{"groupId":"OG001","value":"-2.8","spread":"18.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"22.20"},{"groupId":"OG001","value":"-3.4","spread":"22.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"11.15"},{"groupId":"OG001","value":"-1.8","spread":"11.16"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":123},"commonTop":["Conjunctival Haemorrhage","Nasopharyngitis","Punctate Keratitis","Conjunctival Oedema","Intraocular Pressure Increased"]}}}